Poniard Pharmaceuticals, Inc.
PARD
$0.0001
$0.000.00%
OTC PK
| 09/30/2011 | 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.85% | -10.90% | -7.59% | 14.48% | 14.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.90% | -53.89% | -52.09% | -37.89% | -23.93% |
| Operating Income | 57.90% | 53.89% | 52.09% | 37.89% | 23.93% |
| Income Before Tax | 57.84% | 54.87% | 52.06% | 34.26% | 18.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.84% | 54.87% | 52.06% | 34.26% | 18.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.84% | 54.87% | 52.06% | 34.26% | 18.15% |
| EBIT | 57.90% | 53.89% | 52.09% | 37.89% | 23.93% |
| EBITDA | 60.18% | 55.82% | 53.77% | 38.92% | 24.33% |
| EPS Basic | 67.68% | 65.68% | 63.76% | 48.81% | 31.88% |
| Normalized Basic EPS | 68.55% | 65.12% | 63.03% | 51.75% | 36.95% |
| EPS Diluted | 67.77% | 65.76% | 63.70% | 48.60% | 31.68% |
| Normalized Diluted EPS | 68.55% | 65.12% | 63.03% | 51.75% | 36.95% |
| Average Basic Shares Outstanding | 26.15% | 29.41% | 32.45% | 32.82% | 26.69% |
| Average Diluted Shares Outstanding | 26.15% | 29.41% | 32.45% | 32.82% | 26.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.32% | -0.23% | 0.20% | 0.42% | 0.15% |